Inceptionr LLC Makes New Investment in Dynavax Technologies Co. (NASDAQ:DVAX)

Inceptionr LLC bought a new position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 12,929 shares of the biopharmaceutical company’s stock, valued at approximately $165,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PDT Partners LLC bought a new position in shares of Dynavax Technologies during the 3rd quarter worth about $3,967,000. Nordea Investment Management AB increased its holdings in shares of Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares during the period. Mizuho Markets Americas LLC increased its holdings in shares of Dynavax Technologies by 17.4% during the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares during the period. Barclays PLC increased its holdings in shares of Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock worth $3,371,000 after purchasing an additional 175,118 shares during the period. Finally, Bank of Montreal Can increased its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on DVAX shares. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $14.39 on Tuesday. The stock has a market cap of $1.79 billion, a P/E ratio of 79.94 and a beta of 1.23. The company’s 50-day simple moving average is $13.04 and its 200 day simple moving average is $12.24. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. The business had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.